Join us at SVB’s panel, with corporate and traditional institutional VCs, where we discuss trends in investments and the promise of raising (and closing) capital rounds for early stage ventures over some light refreshments and drinks.

H1 2023 has seen promising activity in the investor fundraising space with a total of $13.7B raised by VCs. If this pace were annualized through 2023, life-science-focused VC fundraising would near 2021’s record pace. This uptick comes amid expectations for a more dovish Fed, a near wholesale resetting of valuation expectations in the private market, and early signs of a rebounding stock market. Savvy investors know these conditions bring opportunity.

Early-stage investment into therapeutics companies jumped this year but at massively reset valuations. Focus is increasingly on companies led by veteran management teams with in-human proof-of-concept/proven modalities with compelling stories at “2023 market prices” and realistic exit prospects that do not rely upon the IPO window opening in the next 12-18 months.

Join us at SVB’s panel, with corporate and traditional institutional VCs, where we discuss trends in investments and the promise of raising (and closing) capital rounds for early stage ventures.

Panel Moderator: Anton Xavier, Director SVB Life Sciences, A Division of First Citizen’s Bank